Semapimod

DRUG4 trials

Sponsors

Ferring Pharmaceuticals

Conditions

Crohn DiseaseCrohn's Disease

Phase 2

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

TerminatedNCT00038766

Ferring PharmaceuticalsCrohn Disease

Start: 2002-06-30End: 2003-06-30Updated: 2012-08-23

Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo

CompletedNCT00739986

Ferring PharmaceuticalsCrohn's Disease

Start: 2002-10-31End: 2004-08-31Updated: 2023-11-09

Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease

CompletedNCT00740103

Ferring PharmaceuticalsCrohn's Disease

Start: 2002-12-31End: 2004-09-30Updated: 2025-03-28

Extension Study of Semapimod 60 mg IV x 3 Days

CompletedNCT00741910

Ferring PharmaceuticalsCrohn's Disease

Start: 2003-07-31End: 2006-06-30Updated: 2023-11-18